NO882918L - Partikkelformede hybride hiv antigener. - Google Patents

Partikkelformede hybride hiv antigener.

Info

Publication number
NO882918L
NO882918L NO88882918A NO882918A NO882918L NO 882918 L NO882918 L NO 882918L NO 88882918 A NO88882918 A NO 88882918A NO 882918 A NO882918 A NO 882918A NO 882918 L NO882918 L NO 882918L
Authority
NO
Norway
Prior art keywords
antigenes
particulated
hybrid hiv
hiv
hybrid
Prior art date
Application number
NO88882918A
Other languages
English (en)
Other versions
NO177794C (no
NO177794B (no
NO882918D0 (no
Inventor
Alan John Kingsman
Susan Mary Kingsman
Sally Elizabeth Adams
Original Assignee
British Bio Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868626148A external-priority patent/GB8626148D0/en
Priority claimed from GB878708532A external-priority patent/GB8708532D0/en
Application filed by British Bio Technology filed Critical British Bio Technology
Publication of NO882918D0 publication Critical patent/NO882918D0/no
Publication of NO882918L publication Critical patent/NO882918L/no
Publication of NO177794B publication Critical patent/NO177794B/no
Publication of NO177794C publication Critical patent/NO177794C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO882918A 1986-11-01 1988-06-30 Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten NO177794C (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB868626148A GB8626148D0 (en) 1986-11-01 1986-11-01 Antigen presentation & purification system
GB878708532A GB8708532D0 (en) 1987-04-09 1987-04-09 Particulate hybrid hiv antigens
US3688887A 1987-04-10 1987-04-10
PCT/GB1987/000763 WO1988003562A1 (en) 1986-11-01 1987-10-28 Particulate hybrid hiv antigens

Publications (4)

Publication Number Publication Date
NO882918D0 NO882918D0 (no) 1988-06-30
NO882918L true NO882918L (no) 1988-08-29
NO177794B NO177794B (no) 1995-08-14
NO177794C NO177794C (no) 1995-11-22

Family

ID=27263195

Family Applications (1)

Application Number Title Priority Date Filing Date
NO882918A NO177794C (no) 1986-11-01 1988-06-30 Fremgangsmåte for fremstilling av et fusjonsprotein, samt nukleinsyre, ekspresjonsvektor og vertscelle som kan anvendes ved fremgangsmåten

Country Status (8)

Country Link
EP (1) EP0329671B1 (no)
JP (1) JPH02501107A (no)
AU (1) AU606627B2 (no)
DE (1) DE3788806T2 (no)
ES (1) ES2010230A6 (no)
HU (1) HUT50875A (no)
NO (1) NO177794C (no)
WO (1) WO1988003562A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3006789A (en) * 1988-02-24 1989-08-24 Smithkline Beckman Corporation Expression of hiv binding proteins
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
WO1994029459A1 (en) 1993-06-04 1994-12-22 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
ATE118247T1 (de) * 1988-09-27 1995-02-15 Dana Farber Cancer Inst Inc Vektor, der ein replikationskompetentes hiv-i- provirus und ein heterologes gen enthält.
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
WO1990005787A1 (en) * 1988-11-23 1990-05-31 The Regents Of The University Of California Position-specific insertion vectors and method of using same
EP1288304A3 (en) * 1989-06-01 2006-04-05 Applied Biotechnology, Inc. Self-assembled, defective, non-self-propagating viral particles
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5989886A (en) * 1991-01-02 1999-11-23 The Johns Hopkins University Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme
GB9107631D0 (en) * 1991-04-10 1991-05-29 British Bio Technology Proteinaceous particles
EP0565794A1 (en) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction of CTL responses
WO1994016084A1 (en) * 1993-01-16 1994-07-21 British Bio-Technology Limited Hybrid particle-forming protein comprising a particle-inducing segment and a plurality of antigens
FR2703996B1 (fr) * 1993-04-16 1995-07-21 Transgene Sa Ensemble de transposition destine au transfert d'un gene d'interet dans le genome d'une cellule eucaryote.
DE4335025A1 (de) * 1993-10-14 1995-04-20 Boehringer Ingelheim Int Endosomolytisch wirksame Partikel
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
US6525173B1 (en) 1997-01-02 2003-02-25 Universidade Federal De Minas Gerais Process for expression and production of recombinant protein hybrid protein (p24/p17) derived from human immunodeficiency viruses (HIV-1)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR76274B (no) * 1981-08-04 1984-08-04 Univ California
DE3788807T2 (de) * 1986-11-01 1994-06-30 British Bio Technology Fusionsproteine und -partikel.

Also Published As

Publication number Publication date
ES2010230A6 (es) 1989-11-01
NO177794C (no) 1995-11-22
EP0329671A1 (en) 1989-08-30
AU606627B2 (en) 1991-02-14
AU8153487A (en) 1988-06-01
DE3788806D1 (de) 1994-02-24
NO177794B (no) 1995-08-14
NO882918D0 (no) 1988-06-30
DE3788806T2 (de) 1994-07-07
HUT50875A (en) 1990-03-28
JPH02501107A (ja) 1990-04-19
EP0329671B1 (en) 1994-01-12
WO1988003562A1 (en) 1988-05-19

Similar Documents

Publication Publication Date Title
NO882918D0 (no) Partikkelformede hybride hiv antigener.
FI875209A7 (fi) Galeeninen valmiste.
ATE58845T1 (de) Spielzeug-zahnradbahn.
FI891548A7 (fi) Administrering av monoaminakridiner i kolinergiska bristtillstaond av nervceller.
FI873622A0 (fi) Komplexa pigmentsammansaettningar foer bestrykning av papper.
DE3766422D1 (de) Integrierte hybridschaltung.
DE3774374D1 (de) Wundheilende zubereitungen.
DE3575707D1 (de) Wirbelerzeuger.
FI873619L (fi) Rf-skyddad hybridkrets.
NO872815L (no) Leket.
DE3787548D1 (de) Makrolid-verbindungen.
FI870377A7 (fi) Viruksenvastaisia koostumuksia.
DE3482389D1 (de) Hybride regulierbare region.
FI864456L (fi) Surt kromhaltigt passiveringsbad foer zink- och kadmiumytor.
DE3778562D1 (de) Digitaler sinusgenerator.
DE3786025D1 (de) Makrolid-verbindungen.
FI871756L (fi) Skyddskrets foer skydd av en abonnentkrets mot oeverspaenningar.
DE3781503D1 (de) Herausspringende spielzeugfigur.
ES1005262Y (es) Generador taquimetrico.
DE3867609D1 (de) Hybride brennstoffzusammensetzung.
FI872043A7 (fi) Merkkigeneraattori.
FI870103A0 (fi) Producering av humanserum albumin i en bacillus-stam.
FI872802A0 (fi) Vaccin mot protozonparasiter.
NO871630D0 (no) Mineralsupplementpreparat.
DK362188A (da) Partikulaere hybride hiv-antigener